Altria Group (NYSE:MO) Stock Rating Reaffirmed by UBS AG
Altria Group (NYSE:MO)‘s stock had its “hold” rating reissued by research analysts at UBS AG in a research report issued on Tuesday.
The analysts wrote, “modest potential negatives.”In fact, the FDA’s new policy on tobacco is the “bigger overhang” as it could evolve into incremental federal cigarette regulation — an event that was previously viewed as being unlikely, the analyst continued. As a result, Altria’s longer-term growth assumptions are being called into question and a re-rating of the stock’s multiple is justified, as has been the case in prior periods of regulatory scrutiny.However, the FDA’s new policy shift will be slow to implement and represents no near-term impacts to Altria’s earnings per share, Powers added. Also, conversations with industry experts suggest that it will take several years before any tangible regulatory change on the industry takes hold.Related Links:Tobacco Reemerges As Hollywood Star, But Does The Screen Time Help?This Biometric ID System Allows You To Buy Weed, Booze And Other Controlled Products From A Vending Machine Posted-In: cigarettesAnalyst Color Price Target FDA Legal Top Stories Analyst Ratings Trading Ideas Best of Benzinga © 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Related Articles (MO) Reality Reflects Art: World Puts Grisly Graphics On Cigarette Packs; US Tries Different Approach Jim Cramer Shares His Thoughts On Sony, Microsoft, Valeant And Altria 5 Biggest Price Target Changes For Monday Benzinga's Top Upgrades, Downgrades For July 31, 2017 Mid-Afternoon Market Update: CyberOptics Drops After Q2 Results; Aaron's Shares Surge FDA's Nicotine Cut: Not As Bad As It Looks? View Comments and Join the Discussion! View the discussion thread. document.write(”) Newsletter & Alerts